Context

Hundreds of millions of people around the world are estimated to be infected by Strongyloides stercoralis.1 Strongyloidiasis is a soil-transmitted helminthiasis that can persist indefinitely in the infected host if not adequately treated, because of a peculiar autoinfective cycle. Chronic infection is characterised by non-specific symptoms of variable intensity (asymptomatic infection can also occur), mainly relating to the gastrointestinal tract. However, strongyloidiasis is particularly relevant because it can cause a severe syndrome in immunocompromised patients (hyperinfection/dissemination), associated with high mortality.2 Therefore, all infected patients, irrespective of presence of symptoms, should receive a treatment that can guarantee a cure, in order to …